A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Efavaleukin alfa (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 11 Sep 2019 Planned End Date changed from 16 Mar 2023 to 15 Jun 2023.
- 11 Sep 2019 Planned primary completion date changed from 16 Mar 2023 to 15 Jun 2023.
- 14 Aug 2019 Planned End Date changed from 11 May 2023 to 16 Mar 2023.